| pubmed-article:6108901 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6108901 | lifeskim:mentions | umls-concept:C0023895 | lld:lifeskim |
| pubmed-article:6108901 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:6108901 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:6108901 | lifeskim:mentions | umls-concept:C0917995 | lld:lifeskim |
| pubmed-article:6108901 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:6108901 | pubmed:dateCreated | 1981-3-17 | lld:pubmed |
| pubmed-article:6108901 | pubmed:abstractText | A randomised double-blind trial of (+)-cyanidanol-3(Catechin), 2 g/day versus placebo, was carried out in 40 patients with pre-cirrhotic alcohol-related liver disease over a three month period. Twenty received the active drug and 20 placebo; one non-compliant patient in the treatment group was withdrawn. Forty-one per cent (16/39) abstained from alcohol and showed significant improvements (P < 0.005) in mean values for serum aspartate transaminase, serum gamma glutamyl transpeptidase, and mean corpuscular volume. Ten of the 16 showed overall histological improvement on liver biopsy. Fifty-nine pr cent (23/39) continued to drink, though significantly reducing their mean daily alcohol intake (P < 0.001). No significant changes occurred in this group in mean serum enzyme values, though the mean value for mean corpuscular volume improved significantly (P < 0.01) and 16 of the 23 showed overall histological improvement. Changes occurred irrespective of treatment with Catechin which suggests that, over a three month period, this drug did not influence the course of alcohol-related liver disease. | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6108901 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:6108901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6108901 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6108901 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:6108901 | pubmed:issn | 0017-5749 | lld:pubmed |
| pubmed-article:6108901 | pubmed:author | pubmed-author:SherlockSS | lld:pubmed |
| pubmed-article:6108901 | pubmed:author | pubmed-author:ScheuerP JPJ | lld:pubmed |
| pubmed-article:6108901 | pubmed:author | pubmed-author:MorganM YMY | lld:pubmed |
| pubmed-article:6108901 | pubmed:author | pubmed-author:ColmanJ CJC | lld:pubmed |
| pubmed-article:6108901 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6108901 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:6108901 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6108901 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6108901 | pubmed:pagination | 965-9 | lld:pubmed |
| pubmed-article:6108901 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:meshHeading | pubmed-meshheading:6108901-... | lld:pubmed |
| pubmed-article:6108901 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:6108901 | pubmed:articleTitle | Treatment of alcohol-related liver disease with (+)-cyanidanol-3: a randomised double-blind trial. | lld:pubmed |
| pubmed-article:6108901 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6108901 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:6108901 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6108901 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6108901 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6108901 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6108901 | lld:pubmed |
